newsfilter
← Latest News
GlobeNewswire·

Ascentage Pharma to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026

  • Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) announced its management will attend the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11-12, 2026.
  • The company's management team will participate in a fireside chat at 9:30 am EST on Thursday, February 12, 2026.
  • The webcast for the event is accessible via the Events page in the Investor Relations section of Ascentage's website.
  • Ascentage Pharma is a global, commercial-stage biopharmaceutical company focused on novel therapies for cancer, including Bcl-2 & MDM2-p53 inhibitors & next-generation kinase inhibitors.
  • The lead asset, Olverembatinib, is a third-generation BCR-ABL1 inhibitor approved in China for CML patients with T315I mutations & those resistant to first/second-generation TKIs, all covered by the China National Reimbursement Drug List.
  • Ascentage is conducting the FDA-cleared POLARIS-2 Phase III trial for Olverembatinib in CML, along with Phase III trials for newly diagnosed Ph+ ALL & SDH-deficient GIST.
  • Lisaftoclax, a Bcl-2 inhibitor approved in China for CLL/SLL patients previously treated with BTK inhibitors, is the company's second approved product.
  • Four global Phase III trials are underway for Lisaftoclax: GLORA (combination with BTK inhibitors for CLL/SLL), GLORA-2 (newly diagnosed CLL/SLL), GLORA-3 (newly diagnosed AML), & GLORA-4 (newly diagnosed HR MDS).
  • The GLORA-4 study received simultaneous clearance from the U.S. FDA, EU EMA, & China CDE.
  • The company maintains global partnerships with Takeda, AstraZeneca, Merck, Pfizer, & Innovent, alongside research collaborations with institutions including Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute, & University of Michigan.
  • The press release includes forward-looking statements subject to risks & uncertainties detailed in the company's SEC filings & Hong Kong IPO prospectus.